Lung Cancer Edition: Top Headlines for Week of June 5, 2023
Manage episode 407442268 series 3560281
In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.
Read the full coverage here:
Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer
First-line combination extends PFS in lung cancer subgroup
Pembrolizumab improves outcomes in early-stage resectable lung cancer
Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC
Severe myelosuppression common after chemotherapy for small cell lung cancer
References:
Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738.
Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles.
Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
119 episodes